CRL Charles River Laboratories International Inc
Price (delayed)
$163.02
Market cap
$8.34B
P/E Ratio
815.1
Dividend/share
N/A
EPS
$0.2
Enterprise value
$10.87B
Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted
Highlights
Charles River Laboratories International's debt has decreased by 11% YoY
The EPS has shrunk by 98% YoY and by 98% QoQ
The net income has dropped by 95% year-on-year and by 95% since the previous quarter
Key stats
What are the main financial stats of CRL
Market
Valuations
Earnings
Shares outstanding
51.14M
Market cap
$8.34B
Enterprise value
$10.87B
Price to earnings (P/E)
815.1
Price to book (P/B)
2.41
Price to sales (P/S)
2.07
EV/EBIT
50.23
EV/EBITDA
18.8
EV/Sales
2.68
Revenue
$4.05B
Gross profit
$1.33B
Operating income
$227.35M
Net income
$22.2M
EBIT
$216.31M
EBITDA
$578.06M
Free cash flow
$501.61M
Per share
Balance sheet
Liquidity
EPS
$0.2
EPS diluted
$0.2
Free cash flow per share
$9.76
Book value per share
$67.69
Revenue per share
$78.82
TBVPS
$77.04
Total assets
$7.53B
Total liabilities
$4.02B
Debt
$2.72B
Equity
$3.46B
Working capital
$408.97M
Debt to equity
0.79
Current ratio
1.41
Quick ratio
0.92
Net debt/EBITDA
4.38
Margins
Efficiency
Dividend
EBITDA margin
14.3%
Gross margin
32.9%
Net margin
0.5%
Operating margin
5.6%
Return on assets
0.1%
Return on equity
0.3%
Return on invested capital
3.8%
Return on capital employed
3.3%
Return on sales
5.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRL stock price
How has the Charles River Laboratories International stock price performed over time
Intraday
0.47%
1 week
7.26%
1 month
-4%
1 year
-32.38%
YTD
-11.69%
QTD
-11.69%
Financial performance
How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.05B
Gross profit
$1.33B
Operating income
$227.35M
Net income
$22.2M
Gross margin
32.9%
Net margin
0.5%
Charles River Laboratories International's net margin has shrunk by 96% YoY and by 95% QoQ
The net income has dropped by 95% year-on-year and by 95% since the previous quarter
CRL's operating income has shrunk by 63% YoY and by 57% QoQ
The operating margin has shrunk by 62% YoY and by 57% QoQ
Growth
What is Charles River Laboratories International's growth rate over time
Valuation
What is Charles River Laboratories International stock price valuation
P/E
815.1
P/B
2.41
P/S
2.07
EV/EBIT
50.23
EV/EBITDA
18.8
EV/Sales
2.68
The EPS has shrunk by 98% YoY and by 98% QoQ
The price to book (P/B) is 49% lower than the 5-year quarterly average of 4.7 and 20% lower than the last 4 quarters average of 3.0
The equity has declined by 8% since the previous quarter and by 3.8% year-on-year
The P/S is 41% lower than the 5-year quarterly average of 3.5 and 23% lower than the last 4 quarters average of 2.7
Efficiency
How efficient is Charles River Laboratories International business performance
The ROE has plunged by 98% YoY and by 97% from the previous quarter
The company's return on assets has shrunk by 98% YoY and by 98% QoQ
The company's return on invested capital has shrunk by 69% YoY and by 65% QoQ
The ROS has shrunk by 69% YoY and by 67% QoQ
Dividends
What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRL.
Financial health
How did Charles River Laboratories International financials performed over time
The company's total assets is 87% higher than its total liabilities
The total liabilities fell by 11% YoY and by 3.7% QoQ
The company's total assets fell by 8% YoY and by 6% QoQ
Charles River Laboratories International's debt is 21% lower than its equity
Charles River Laboratories International's debt has decreased by 11% YoY
Charles River Laboratories International's debt to equity has increased by 8% from the previous quarter but it has decreased by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.